Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell. 2021

Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
College of Pharmaceutical Science & Green Pharmaceutical Collaborative Innovation Center of Yangtze River Delta Region, Zhejiang University of Technology, Hangzhou, 310014, China.

P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is a phenomenon in which cells become resistant to structurally and mechanistically unrelated drugs resulting in low intracellular drug concentrations. It is one of the noteworthy problems in malignant tumor clinical therapeutics. So P-gp protein is one of the ideal targets to solve MDR. Based on the lead compound 5m obtained from our previous work, a series of furan derivatives featuring alkyl-substituted phenols and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline were designed and synthesized as reversal agents against P-gp in this paper. Compound 16 containing isopropoxy possessed good potency against P-gp mediated MDR in MCF-7/ADR (IC50 (doxorubicin) = 0.73 μM, RF = 69.6 with 5 μM 16 treated). Western blot results and Rh123 accumulation assays showed that 16 effectively inhibited P-gp efflux function but not its expression. The preliminary structure-activity relationship and docking studies demonstrated that compound 16 would be a potential P-gp inhibitor. Most worthy of mention is that compound 16 has achieved satisfactory results in combination with a variety of anti-tumor drugs, such as doxorubicin, paclitaxel, and vincristine. This study forwards a hopeful P-gp inhibitor for withstanding malignant tumor cell with multidrug resistance setting the basis for further studies.

UI MeSH Term Description Entries
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D044005 Tetrahydroisoquinolines A group of ISOQUINOLINES in which the nitrogen containing ring is protonated. They derive from the non-enzymatic Pictet-Spengler condensation of CATECHOLAMINES with ALDEHYDES. Tetrahydro-Isoquinoline,1,2,3,4-Tetrahydroisoquinolines,Tetrahydro-Isoquinolines,Tetrahydro Isoquinoline,Tetrahydro Isoquinolines
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
March 2024, Scientific reports,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
March 2024, European journal of medicinal chemistry,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
January 2019, Frontiers in chemistry,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
June 2015, Fitoterapia,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
December 2019, European journal of medicinal chemistry,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
April 2017, Journal of medicinal chemistry,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
September 2019, Bioorganic chemistry,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
June 2016, Molecular medicine reports,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
May 2016, Bioorganic & medicinal chemistry,
Ya-Sheng Li, and Xi Yang, and Dong-Sheng Zhao, and Yue Cai, and Zhi Huang, and Rui Wu, and Si-Jia Wang, and Gui-Jun Liu, and Jian Wang, and Xiao-Ze Bao, and Xin-Yi Ye, and Bin Wei, and Zi-Ning Cui, and Hong Wang
January 2017, Drug design, development and therapy,
Copied contents to your clipboard!